Thalidomide and thrombosis in multiple myeloma

被引：23

作者：

Barbui, T ^{[1
]}

Falanga, A ^{[1
]}

机构：

[1] Osped Riuniti Bergamo, Dept Hematol, I-24128 Bergamo, Italy

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2003年 / 1卷 / 03期

关键词：

INCREASED RISK;

D O I：

10.1046/j.1538-7836.2003.00084.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：421 / 422

页数：2

共 10 条

[1] Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients [J].

Barlogie, B ;

Desikan, R ;

Eddlemon, P ;

Spencer, T ;

Zeldis, J ;

Munshi, N ;

Badros, A ;

Zangari, M ;

Anaissie, E ;

Epstein, J ;

Shaughnessy, J ;

Ayers, D ;

Spoon, D ;

Tricot, G .

BLOOD, 2001, 98 (02) :492-494

[2] Thalidomide in the management of multiple myeloma [J].

Barlogie, B ;

Zangari, M ;

Spencer, T ;

Fassas, A ;

Anaissie, E ;

Badros, A ;

Cromer, J ;

Tricot, G .

SEMINARS IN HEMATOLOGY, 2001, 38 (03) :250-259

[3] Pathophysiology of the thrombophilic state in the cancer patient [J].

Falanga, A ;

Rickles, FR .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1999, 25 (02) :173-182

[4] Coagulopathy of acute promyelocytic leukemia [J].

Falanga, A ;

Barbui, T .

ACTA HAEMATOLOGICA, 2001, 106 (1-2) :43-51

[5] Deep venous thrombosis and thalidomide therapy for multiple myeloma. [J].

Osman, K ;

Comenzo, R ;

Rajkumar, SV .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1951-1952

[6] Epidemiology of thrombosis in cancer [J].

Rickles, FR ;

Levine, MN .

ACTA HAEMATOLOGICA, 2001, 106 (1-2) :6-12

[7] Antitumor activity of thalidomide in refractory multiple myeloma. [J].

Singhal, S ;

Mehta, J ;

Desikan, R ;

Ayers, D ;

Roberson, P ;

Eddlemon, P ;

Munshi, N ;

Anaissie, E ;

Wilson, C ;

Dhodapkar, M ;

Zeldis, J ;

Barlogie, B ;

Siegel, D ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (21) :1565-1571

[8] Thromboembolic events during treatment with thalidomide [J].

Urbauer, E ;

Kaufmann, H ;

Nösslinger, T ;

Raderer, M ;

Drach, J .

BLOOD, 2002, 99 (11) :4247-4248

[9] Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications [J].

Zangari, M ;

Saghafifar, F ;

Anaissie, E ;

Badros, A ;

Desikan, R ;

Fassas, A ;

Mehta, P ;

Morris, C ;

Toor, A ;

Whitfield, D ;

Siegel, E ;

Barlogie, B ;

Fink, L ;

Tricot, G .

BLOOD COAGULATION & FIBRINOLYSIS, 2002, 13 (03) :187-192

[10] Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy [J].

Zangari, M ;

Anaissie, E ;

Barlogie, B ;

Badros, A ;

Desikan, R ;

Gopal, AV ;

Morris, C ;

Toor, A ;

Siegel, E ;

Fink, L ;

Tricot, G .

BLOOD, 2001, 98 (05) :1614-1615

← 1 →